Search Results - therapeutics

6 Results Sort By:
Primary cilium-polycystin complex, a novel mechanosensing pathway in bone
Reference: PD 12083The Problem The skeleton adapts to alterations in mechanical loading by changing bone structure. Increased load results in increased bone mass as a result of increased osteoblast-mediated bone formation , whereas skeletal unloading, which occurs with immobilization, disuse, and exposure to low gravity, leads to low bone mass from...
Published: 6/13/2013   |   Updated: 6/12/2013   |   Inventor(s): Zhousheng Xiao, L. Darryl Quarles
Keywords(s): Therapeutics
Category(s): Human Health
Two monoclonal antibodies that specifically inhibit plasminogen activated induced by TPA
Reference: PD 13059  The Problem Although tissue plasminogen activator (TPA) is an effective therapy for ischemic stroke, it also causes severe and fatal bleeding in some patients.  Fear of bleeding and the lack of a specific antidote has led to widespread underuse of TPA by physicians. Serious bleeding occurs in 7-9% of ischemic stroke patients treated...
Published: 6/13/2013   |   Updated: 6/12/2013   |   Inventor(s): Guy Reed
Keywords(s): Biologics, Cardiovascular, Therapeutics
Category(s): Human Health
The use of asialo-galactosylated triantennary oligosaccharides and their derivatives to support photoreceptor outer segment membrane assembly
Reference: PD06050The Problem Age-related Macular Degeneration (AMD) affects millions of people, progressively robbing them of their central vision and significantly reducing their quality of life. Without central vision, they are unable to read, recognize faces, drive, or perform countless daily activities. The vast majority of AMD cases consist of...
Published: 6/13/2013   |   Updated: 6/11/2013   |   Inventor(s): Monica Jablonski
Keywords(s): Ophthalmology, Therapeutics
Category(s): Human Health
Gene delivery of a mutant form of erythropoietin preserves neuronal cell bodies, axons, and function.
The Problem Glaucoma is a leading cause of blindness worldwide and affects approximately 4 million people in the United States. Currently, there is no cure for glaucoma and any vision loss that occurs is permanent. Current treatments include daily drops and pills aimed at lowering the intraocular pressure (IOP). New treatments are needed to 1) address...
Published: 6/5/2013   |   Updated: 6/4/2013   |   Inventor(s): Tonia Rex, Tim Sullivan
Keywords(s): Gene delivery, Gene therapy, Ophthalmology, Therapeutics
Category(s): Human Health
A Toll-like Receptor (TLR)/Interleukin 1 Receptor (IL-1R) Pathway-specific Protein Kinase D1 Inhibitor
Reference: PD 13047 Technical Field Novel targets: Inflammatory and autoimmune diseases ­ The Technology Toll-like receptor (TLR)/interleukin 1 receptor (IL-1R) signaling plays a critical pathogenic role in many forms of inflammatory and...
Published: 6/4/2013   |   Updated: 5/21/2013   |   Inventor(s): AE-Kyung Yi, JeounG-Eun Park
Keywords(s): Arthritis, Autoimmune, Inflammatory, Peptides, Protein Kinase D1, Therapeutics
Category(s): Human Health
Discovery of Selective Menaquinone Biosynthesis Inhibitors against Mycobacterium tuberculosis
Reference: PD 12060 Therapeutic: Antibacterial Background Mycobacterium tuberculosis (Mtb) causes tuberculosis (TB) and is responsible for nearly two million deaths annually. Moreover, the emergence of multidrug-resistant (MDR) strains of Mtb seriously threatens TB control and prevention efforts. M. tuberculosis is recognized to lie in a non-replicating...
Published: 6/4/2013   |   Updated: 5/21/2013   |   Inventor(s): Michio Kurosu, Joy Debnath, Shajila Siricilla
Keywords(s): Anti-bacterial, Bacteria, Small molecule, Therapeutics, Tuberculosis
Category(s): Human Health